Enliven Therapeutics, Inc. $ELVN Shares Bought by Candriam S.C.A.

Candriam S.C.A. raised its stake in shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) by 31.1% during the first quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 594,079 shares of the company’s stock after buying an additional 141,060 shares during the quarter. Candriam S.C.A.’s holdings in Enliven Therapeutics were worth $23,288,000 at the end of the most recent reporting period.

Several other hedge funds also recently bought and sold shares of ELVN. Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of Enliven Therapeutics by 25.9% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,884 shares of the company’s stock worth $44,000 after acquiring an additional 594 shares during the last quarter. BNP Paribas Financial Markets increased its stake in Enliven Therapeutics by 33.3% in the second quarter. BNP Paribas Financial Markets now owns 3,722 shares of the company’s stock valued at $75,000 after purchasing an additional 930 shares during the last quarter. Quantbot Technologies LP grew its holdings in Enliven Therapeutics by 47.1% in the 2nd quarter. Quantbot Technologies LP now owns 4,477 shares of the company’s stock valued at $90,000 after buying an additional 1,434 shares during the period. Tower Research Capital LLC TRC increased its stake in shares of Enliven Therapeutics by 194.3% during the 2nd quarter. Tower Research Capital LLC TRC now owns 5,286 shares of the company’s stock valued at $106,000 after acquiring an additional 3,490 shares during the last quarter. Finally, Los Angeles Capital Management LLC acquired a new position in shares of Enliven Therapeutics during the 4th quarter valued at about $83,000. Hedge funds and other institutional investors own 95.08% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on ELVN. Wall Street Zen raised shares of Enliven Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday, May 11th. The Goldman Sachs Group increased their price target on shares of Enliven Therapeutics from $41.00 to $59.00 and gave the stock a “buy” rating in a research note on Friday, May 8th. HC Wainwright boosted their price objective on shares of Enliven Therapeutics from $56.00 to $64.00 and gave the company a “buy” rating in a research note on Thursday. Weiss Ratings restated a “sell (d-)” rating on shares of Enliven Therapeutics in a report on Monday, April 20th. Finally, JonesTrading increased their target price on Enliven Therapeutics from $45.00 to $70.00 and gave the stock a “buy” rating in a research report on Monday, June 29th. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $69.17.

Insider Buying and Selling

In other Enliven Therapeutics news, CFO Benjamin Hohl sold 6,018 shares of the stock in a transaction that occurred on Wednesday, June 17th. The stock was sold at an average price of $43.80, for a total transaction of $263,588.40. Following the transaction, the chief financial officer owned 51,000 shares of the company’s stock, valued at $2,233,800. This trade represents a 10.55% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Lori Anne Kunkel sold 10,000 shares of Enliven Therapeutics stock in a transaction that occurred on Friday, June 5th. The stock was sold at an average price of $34.54, for a total value of $345,400.00. Following the completion of the transaction, the director owned 51,884 shares of the company’s stock, valued at approximately $1,792,073.36. The trade was a 16.16% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 26,018 shares of company stock worth $1,113,888. 3.00% of the stock is currently owned by company insiders.

Enliven Therapeutics Stock Down 2.1%

Shares of Enliven Therapeutics stock traded down $1.09 during trading hours on Friday, hitting $51.09. 623,677 shares of the company’s stock traded hands, compared to its average volume of 2,183,390. The company has a market cap of $3.11 billion, a PE ratio of -30.59 and a beta of 0.24. The stock has a 50 day simple moving average of $43.30 and a 200-day simple moving average of $34.74. Enliven Therapeutics, Inc. has a twelve month low of $14.78 and a twelve month high of $52.39.

Enliven Therapeutics (NASDAQ:ELVN) last issued its quarterly earnings results on Thursday, May 7th. The company reported ($0.38) EPS for the quarter, topping the consensus estimate of ($0.44) by $0.06. As a group, equities research analysts predict that Enliven Therapeutics, Inc. will post -1.57 EPS for the current year.

Enliven Therapeutics Profile

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.